Accuray presents single day prostate radiotherapy approach at ESTRO26 with CyberKnife

Accuray presents single day prostate radiotherapy approach at ESTRO26 with CyberKnife
Accuray unveils PRO-FAST trial

Accuray has introduced a novel strategy for prostate cancer treatment, unveiling the PRO-FAST protocol at ESTRO26 in Milan. The approach utilizes single-day, single-fraction radiotherapy for prostate cancer patients, delivered through the CyberKnife system.

Dr. Fodor and Dr. Broggi from the IRCCS San Raffaele Scientific Institute shared clinical insights on the PRO-FAST method, which aims to significantly reduce the treatment timeline for eligible patients. The initiative underscores the growing trend towards patient-centric, accelerated cancer therapies leveraging advanced radiotherapy technologies.

Accuray has previously highlighted new pediatric radiotherapy developments at ESTRO26 through its Radixact platform, as presented by Dr Liam Herbert at the conference. The company also presented on the integration of AI in radiotherapy, focusing on clinical performance and ethical considerations during an ESTRO session. These efforts form part of Accuray’s continued emphasis on advanced radiotherapy solutions at international forums.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.